EU Regulators Undertake Rolling Review of Pfizer and BioNTech Vaccine Candidate
The COVID-19 vaccine race is reaching the final stages, at least in Europe.
On Oct. 1, the European Medicines Agency (EMA) launched a "rolling review" of phase 3 trial data from AstraZeneca and Oxford University for their COVID-19 vaccine candidate, AZD1222. On Tuesday, the EMA announced it had begun a rolling review of vaccine candidate data from partners Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) as well.
The two companies are collaborating on an RNA vaccine candidate for the novel coronavirus named BNT162b2, which is currently in phase 3 trials.
Source Fool.com
